Abstract
BackgroundAn angiomyolipoma usually occurs in the kidneys and rarely in the liver. Hepatic epithelioid angiomyolipoma (HEAML), a rare variant of angiomyolipoma, possesses malignant potential and mimics the imaging features of hepatocellular carcinoma. Sonazoid® (perfluorobutane microbubbles), a new contrast agent that facilitates hepatic parenchyma-specific Kupffer phase imaging on contrast-enhanced ultrasonography (CEUS), is useful for the detection and characterization of focal liver lesions.Case presentationA 30-year-old man with HEAML underwent CEUS using Sonazoid®, in which new concepts for ultrasonography-based differentiation between HEAML and hepatocellular carcinoma were applied.ConclusionsThis case report provides clinicians and radiologists with a reference for distinguishing HEAML from hepatocellular carcinoma based on CEUS using Sonazoid®.
Highlights
An angiomyolipoma usually occurs in the kidneys and rarely in the liver
Hepatic epithelioid angiomy‐ olipoma (HEAML) is mainly composed of epithelioid cells that possess malignant potential [2]
This case study aimed to analyze the contrast-enhanced ultrasonography (CEUS) characteristics of HEAML using the Sonazoid contrast agent, and to devise new concepts to discrimination between HEAML and hepatocellular carcinoma (HCC)
Summary
An angiomyolipoma usually occurs in the kidneys and rarely in the liver. Hepatic epithelioid angiomy‐ olipoma (HEAML), a rare variant of angiomyolipoma, possesses malignant potential and mimics the imaging features of hepatocellular carcinoma. Contrast-enhanced ultrasonography (CEUS) performed using a blood-pool contrast agent has demonstrated high sensitivity and specificity for characterizing focal liver lesions [5]. This case study aimed to analyze the CEUS characteristics of HEAML using the Sonazoid contrast agent, and to devise new concepts to discrimination between HEAML and HCC. CEUS revealed that the lesion was filled with the contrast agent, its center was moderately enhancing, and the peripheral area was hyperenhancing in the arterial phase.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
